Core Insights - Abivax has appointed Dr. Dominik Höchli to its Board of Directors, bringing extensive experience in immunology and biopharma, particularly from his 20-year tenure at AbbVie/Abbott [1][2][4] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [5] - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [5] Leadership Experience - Dr. Höchli has over two decades of leadership experience in global biopharma, including roles as Vice President of Global Marketing for Immunology and Head of Global Medical Affairs at AbbVie [2][3] - He also served as Interim CEO of Catapult Therapeutics and is the founder of Abinode, a pharmaceutical strategy consulting firm [3] Strategic Importance - The appointment of Dr. Höchli is seen as pivotal for Abivax as it approaches key clinical and regulatory milestones for obefazimod, with a Phase 3 data readout for ulcerative colitis expected in Q3 2025 [2][4]
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors